Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.81 |
| ▸ | PPARG | P37231 | 2/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 8/20 | 0.41 |
| ▸ | PRKCA | P17252 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29655295 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL30689554 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL17819377 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL1132969 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL1254547 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL4445694 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL1744226 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL8168856 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL114922 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 | |
| SCHEMBL1179464 | 1.00 | CYP1A2 (0.81) | CYP1A2PPARGEPHX1ALDH1A1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6639089-B2 | Therapy, side effect reduction | SODA AROMATIC CO., LTD. | 2003-10-28 | — | — | US | claimed |
| US-20030055105-A1 | Anticancer agents, perfumes or foods and drinks containing omega-hydroxyfatty acids | SODA AROMATIC CO., LTD. A JAPANESE CORPORATION (JP) | 2003-03-20 | — | — | US | claimed |
| EP-1249236-A1 | ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING $g(v)-HYDROXYFATTY ACIDS | SODA AROMATIC COMPANY, LIMITED (JP) | 2002-10-16 | — | — | EP | claimed |
| US-6639089-B2 | Therapy, side effect reduction | SODA AROMATIC CO., LTD. | 2003-10-28 | — | — | US | disclosed |
| US-20030055105-A1 | Anticancer agents, perfumes or foods and drinks containing omega-hydroxyfatty acids | SODA AROMATIC CO., LTD. A JAPANESE CORPORATION (JP) | 2003-03-20 | — | — | US | disclosed |
| EP-1249236-A1 | ANTICANCER AGENTS, PERFUMES OR FOODS AND DRINKS CONTAINING $g(v)-HYDROXYFATTY ACIDS | SODA AROMATIC COMPANY, LIMITED (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055105-A1 | Anticancer agents, perfumes or foods and drinks containing omega-hydroxyfatty acids | ALOX5, ELOVL5, ELOVL3 | CYP1A2 640/4885PPARG 192/4885EPHX1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.